Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue declined -0.8% vs FY2018 Q1 pro-forma revenue[1] · Takeda’s 14 global brands, with an aggregate revenue of 270.2 billion yen posted strong year-over-year growth of +22%. This growth mostly offset the negative impact from intensified competition, phasing, and generic erosion. · Takeda’s 5 key business areas represent ~78% of revenues. GI grew +8% spearheaded by ENTYVIO continuing to gain market share. ...